Compare Quest Diagnostics Inc (DGX) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Northrop Grumman Corporation — how do they compare? Quest Diagnostics Inc trades at $231.12 (market cap $25.48B), while Northrop Grumman Corporation trades at $482.49 (market cap $68.83B). The key difference: Northrop Grumman Corporation is far larger — about 2.7× Quest Diagnostics Inc's market cap, and Northrop Grumman Corporation pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Northrop Grumman Corporation for 81 Days on average.
| DGX | NOC | |
|---|---|---|
Market Cap | $25.48B | $68.83B |
Volume | 941,866 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $247.45 | $768.02 |
52-Week Low | $173.49 | $473.46 |
Typical Hold Time | 56 Days | 81 Days |
Enterprise Value | $31.23B | $82.81B |
Dividend Yield | 1.49% | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Northrop Grumman (NOC) trades at $479.00, up 1.17% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations, supported by a robust $104.7 billion backlog and expanding defense budgets. Recent news highlights both competitive pressures from Boeing's $20B fighter contract win and positive developments in F-35 radar demand.
The investment outlook remains positive with analyst consensus at $600.62 (25% upside) and 54% buy ratings, though technical indicators suggest near-term pressure. Key risks include contract competition and execution challenges on major programs like the B-21 bomber, while strong cash flow generation and dividend growth provide shareholder support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
